Elisabetta Magistretti Sells 2,045 Shares of Stevanato Group (NYSE:STVN) Stock

Posted by Stanley Muller on Aug 12th, 2026

Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) Director Elisabetta Magistretti sold 2,045 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €41,084.05. Following the completion of the sale, the director owned 2,930 shares of the company’s stock, valued at approximately €58,863.70. This trade represents a 41.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stevanato Group Trading Down 0.2%

Shares of STVN stock opened at €21.02 on Wednesday. Stevanato Group S.p.A. has a 12 month low of €12.89 and a 12 month high of €28.00. The company has a market cap of $6.36 billion, a PE ratio of 37.53, a price-to-earnings-growth ratio of 1.72 and a beta of 0.77. The company has a quick ratio of 1.08, a current ratio of 1.61 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average is €18.88 and its two-hundred day moving average is €16.99.

Analyst Ratings Changes

A number of research firms have issued reports on STVN. TD Cowen upgraded shares of Stevanato Group to a “strong-buy” rating in a report on Wednesday, June 17th. Wolfe Research started coverage on Stevanato Group in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 price objective on the stock. Finally, Weiss Ratings raised Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Stevanato Group presently has a consensus rating of “Buy”.

View Our Latest Stock Report on Stevanato Group

Institutional Investors Weigh In On Stevanato Group

Several large investors have recently modified their holdings of the stock. First Bank & Trust increased its holdings in Stevanato Group by 3.4% during the 2nd quarter. First Bank & Trust now owns 18,417 shares of the company’s stock worth $333,000 after purchasing an additional 603 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of Stevanato Group by 22.6% in the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after purchasing an additional 773 shares in the last quarter. GW&K Investment Management LLC boosted its position in shares of Stevanato Group by 76.2% during the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after buying an additional 1,055 shares during the period. Pathstone Holdings LLC boosted its position in shares of Stevanato Group by 1.5% during the third quarter. Pathstone Holdings LLC now owns 71,178 shares of the company’s stock worth $1,833,000 after buying an additional 1,067 shares during the period. Finally, Mariner LLC boosted its position in shares of Stevanato Group by 6.9% during the third quarter. Mariner LLC now owns 25,447 shares of the company’s stock worth $655,000 after buying an additional 1,638 shares during the period.

Stevanato Group Company Profile

(Get Free Report)

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.